Amgen Inc. AMGN

Company Overview

Amgen Inc. is a global biotechnology company focused on the discovery, development, manufacturing, and commercialization of human therapeutics. The company operates primarily within the biopharmaceutical industry, targeting serious illnesses with high unmet medical need. Amgen’s products are largely biologics, including recombinant proteins, monoclonal antibodies, and other advanced therapies, with core therapeutic areas spanning oncology, cardiovascular disease, inflammation, bone health, nephrology, and rare diseases.

Amgen generates revenue through the sale of branded medicines to healthcare providers, hospitals, and wholesalers, primarily in developed markets. Key products include therapies for cancer, autoimmune disorders, osteoporosis, and cardiovascular conditions, as well as biosimilars that compete with established biologic drugs. Founded in 1980, Amgen was among the earliest biotechnology companies to successfully commercialize recombinant DNA-based medicines, evolving from a research-driven startup into one of the world’s largest independent biotechnology firms.